ST
CLDX icon

Spot Trading’s Celldex Therapeutics CLDX Stock Holding History

Spot Trading’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-347
Closed -$55K – 3649
2015
Q3 		$55K Buy
+347
New +$98.2K ﹤0.01% 3255
2015
Q2 		– Sell
-287
Closed -$120K – 3893
2015
Q1 		$120K Sell
287
-4,966
-95% -$1.78M ﹤0.01% 3009
2014
Q4 		$1.44M Buy
5,253
+2,800
+114% +$696K 0.01% 1640
2014
Q3 		$477K Buy
2,453
+2,106
+607% +$459K ﹤0.01% 2595
2014
Q2 		$85K Buy
+347
New +$78.3K ﹤0.01% 3749
2014
Q1 		– Sell
-2,273
Closed -$826K – 4218
2013
Q4 		$826K Buy
2,273
+1,666
+274% +$642K ﹤0.01% 2112
2013
Q3 		$322K Hold
607
– – ﹤0.01% 2716
2013
Q2 		$142K Buy
+607
New +$120K ﹤0.01% 3273

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Spot Trading's CLDX Position: Q3 2016 in Review

Spot Trading sold out of Celldex Therapeutics (CLDX) in Q3 2016, closing a stake of 343 shares — an estimated $23K sold.

Spot Trading first reported a position in CLDX in Q2 2013 and held it in 6 quarters. The position peaked at $285K in Q1 2015. 139 funds tracked by Wall St. Rank hold CLDX as of Q3 2016.

  • Spot Trading reported no remaining Celldex Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Spot Trading sold 343 Celldex Therapeutics shares in Q3 2016, an estimated $23K.
  • Spot Trading first reported a position in Celldex Therapeutics in Q2 2013 and held it in 6 quarters.
  • Spot Trading's Celldex Therapeutics position peaked at $285K in Q1 2015.
  • 139 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2016.

Based on Spot Trading's 13F filing for Q3 2016, filed 31 Oct 2016.